Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.02859-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Shohei Minami und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED), MEXT | JST | Moonshot Research and Development Program (Moonshot).
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes several host proteases to cleave the spike (S) protein to enter host cells. SARS-CoV-2 S protein is cleaved into S1 and S2 subunits by furin, which is closely involved in the pathogenicity of SARS-CoV-2. However, the effects of the modulated protease cleavage activity due to S protein mutations on viral replication and pathogenesis remain unclear. Herein, we serially passaged two SARS-CoV-2 strains in Vero cells and characterized the cell-adapted SARS-CoV-2 strains in vitro and in vivo . The adapted strains showed high viral growth, effective S1/S2 cleavage of the S protein, and low pathogenicity compared with the wild-type strain. Furthermore, the viral growth and S1/S2 cleavage were enhanced by the combination of the Δ68–76 and H655Y mutations using recombinant SARS-CoV-2 strains generated by the circular polymerase extension reaction. The recombinant SARS-CoV-2 strain, which contained the mutation of the adapted strain, showed increased susceptibility to the furin inhibitor, suggesting that the adapted SARS-CoV-2 strain utilized furin more effectively than the wild-type strain. Pathogenicity was attenuated by infection with effectively cleaved recombinant SARS-CoV-2 strains, suggesting that the excessive cleavage of the S proteins decreases virulence. Finally, the high-growth-adapted SARS-CoV-2 strain could be used as the seed for a low-cost inactivated vaccine; immunization with this vaccine can effectively protect the host from SARS-CoV-2 variants. Our findings provide novel insights into the growth and pathogenicity of SARS-CoV-2 in the evolution of cell-cell transmission. IMPORTANCE The efficacy of the S protein cleavage generally differs among the SARS-CoV-2 variants, resulting in distinct viral characteristics. The relationship between a mutation and the entry of SARS-CoV-2 into host cells remains unclear. In this study, we analyzed the sequence of high-growth Vero cell-adapted SARS-CoV-2 and factors determining the enhancement of the growth of the adapted virus and confirmed the characteristics of the adapted strain by analyzing the recombinant SARS-CoV-2 strain. We successfully identified mutations Δ68-76 and H655Y, which enhance viral growth and the S protein cleavage by furin. Using recombinant viruses enabled us to conduct a virus challenge experiment in vivo . The pathogenicity of SARS-CoV-2 introduced with the mutations Δ68-76, H655Y, P812L, and Q853L was attenuated in hamsters, indicating the possibility of the attenuation of excessive cleaved SARS-CoV-2. These findings provide novel insights into the infectivity and pathogenesis of SARS-CoV-2 strains, thereby significantly contributing to the field of virology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
- Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
- Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan.
- The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
- Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
- Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
ORCID-Profile: Shohei Minami, Takeshi Kobayashi
Förderung
- Japan Agency for Medical Research and Development (AMED)
- MEXT | JST | Moonshot Research and Development Program (Moonshot)
Zitieren
APA
Minami, S., Kotaki, T., Sakai, Y., Okamura, S., Torii, S., Ono, C., Motooka, D., Hamajima, R., Nouda, R., Nurdin, J. A., Yamasaki, M., Kanai, Y., Ebina, H., Maeda, Y., Okamoto, T., Tachibana, T., Matsuura, Y., & Kobayashi, T. (2024). Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02859-23
Vancouver
Minami S, Kotaki T, Sakai Y, Okamura S, Torii S, Ono C, et al. Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage. Microbiology Spectrum. 2024. doi:10.1128/spectrum.02859-23
BibTeX
@article{Minami2024,
author = {Minami, Shohei and Kotaki, Tomohiro and Sakai, Yusuke and Okamura, Shinya and Torii, Shiho and Ono, Chikako and Motooka, Daisuke and Hamajima, Rina and Nouda, Ryotaro and Nurdin, Jeffery A and Yamasaki, Moeko and Kanai, Yuta and Ebina, Hirotaka and Maeda, Yusuke and Okamoto, Toru and Tachibana, Taro and Matsuura, Yoshiharu and Kobayashi, Takeshi},
title = {Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.02859-23}
}
EUVIMED